Research & Development In Brief
Coffee reduces ovarian cancer: Caffeine may reduce the risk of ovarian cancer, particularly in women who do not use hormones, according to the March 1 journal CANCER, which revealed findings of Shelley S. Tworoger, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, et al. "The potential reduction in risk with higher caffeine intake appeared to be strongest for women who had never used oral contraceptives or postmenopausal hormones," an abstract of the study notes. Researchers also found cigarette smoking may only increase the risk for mucinous ovarian tumors, and alcohol intake is not associated with risk. Researchers gleaned data from questionnaires from the Nurses' Health Study, examining associations between caffeine or alcohol and ovarian cancer risk among 80,253 women between 1976 and 2004. Tworoger, et al. claim more research is needed...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.
Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.